BioPharmSignal logoBioPharmSignal

Biotech News

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics (SRPT)Sarepta Therapeutics2026-06-30 20:25 ESTCompany update

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 30, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024

Open original release

Related news

SRPTSarepta Therapeutics2026-06-30 12:30 EST

Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®

SRPTSarepta Therapeutics2026-06-25 13:46 EST

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

SRPTSarepta Therapeutics2026-06-25 13:46 EST

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

SRPTSarepta Therapeutics2026-06-25 13:46 EST

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

SRPTSarepta Therapeutics2026-06-25 13:46 EST

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

SRPTSarepta Therapeutics2026-06-25 13:46 EST

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

SRPTSarepta Therapeutics2026-06-25 13:46 EST

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress

SRPTSarepta Therapeutics2026-06-25 13:46 EST

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

SRPTSarepta Therapeutics2026-06-25 13:46 EST

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

SRPTSarepta Therapeutics2026-06-25 13:46 EST

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

View all latest news

Sarepta Therapeutics

Sarepta Therapeutics is a genetic medicines company focused on neuromuscular disease, with investors watching how its RNA and gene-therapy programs translate into durable clinical and commercial value.

Recent company news

SRPTZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

SRPTZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

SRPTBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

SRPTGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

SRPTMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close
18.82 USD
Market cap
2B USD
Exchange
NASDAQ
Sector
Biotechnology
Location
United States